European Pharmaceutical Review

NOVEMBER 12, 2024

To boost AstraZeneca’s research and manufacturing footprint by the end of 2026, it is dedicating $3.5 Overall, the biopharma firm explained that these initial US investments are part of AstraZeneca’s plan to attain $80 billion in Total Revenue by the end of the decade. billion of capital investment in the US.

Manufacturing 59

Manufacturing Biopharma Healthcare Healthcare 59

European Pharmaceutical Review

JULY 21, 2023

The company intends to invest approximately $90 million at its site in Ljubljana, Slovenia, to establish a dedicated Sandoz Biopharma Development Center by 2026. They drive competition and cost savings, helping to address the rising financial pressures faced by global healthcare systems.

Biopharma 98

Biopharma Manufacturing Competition Healthcare 98

Clarivate

APRIL 18, 2024

Strategy #1: innovate and create Amazon founder Jeff Bezos has said that overnight success takes about 10 years — and that ramp-up period may be what’s playing out for the ecommerce giant in healthcare. billion, following an earlier failed healthcare venture with Berkshire Hathaway and JPMorgan Chase.

Retail 52

Retail Healthcare Healthcare Physicians 52

Clarivate

APRIL 24, 2023

healthcare payers and providers are consolidating at a dizzying clip as they seek to gain market share, increase access to care and secure clinical control to improve health outcomes. Oak Street has 169 locations across 21 states and expects to nearly double its size to 300 centers by 2026.

Healthcare 89

Healthcare Healthcare Marketing Physicians 89

European Pharmaceutical Review

SEPTEMBER 15, 2023

CUBIC CRO Service Dr Ferrer Biopharma: GentleMist Technology IamFluidics B.V.: Revolutionising microencapsulation with in-air microfluidics technology for next-generation sustainable healthcare solutions. .: CUBIC CRO Service Dr Ferrer Biopharma: GentleMist Technology IamFluidics B.V.:

Pharma 119

Pharma Manufacturing Biopharma Pharmaceutical 119

Clarivate

OCTOBER 25, 2023

The initial list, which takes effect in 2026, has the potential to roil formularies since it includes a mix of high-volume, preferred brands and a group of high-cost specialty drugs for autoimmune conditions (psoriasis) and cancer. Part D cannot cover drugs covered under Part A or Part B , forcing them to be addressed separately.

Prescription 52

Prescription Physicians Manufacturing Healthcare 52

Clarivate

AUGUST 7, 2024

For Medicare, CMS intends to begin directly negotiating prices with drug manufacturers for ten highest-cost drugs starting in 2026 , with plans to expand further, subtly impacting the role of these. Click here to learn more about how Clarivate helps biopharma companies navigate market access across global markets.

Retail 59

Retail Marketing Competition Biopharma 59